Longevity in Russia

Center for Strategic Planning, of the Federal Medical and Biological Agency

Status: Enrolling

Conditions: Aging Disorder; Aging; LONGEVITY 1; Age-related Cognitive Decline; Frailty

Study type: Observational

Funder types: Other

Identifiers

NCT06268132

MLS90

Details and patient eligibility

About

This is an observational cohort study of long-living adults (participants aged 90 and above) from the Central Federal District of Russia.

The study seeks to determine the genetic and cellular and molecular determinants of healthy longevity and to assess the impact of lifestyle and socioeconomic and environmental factors on healthy longevity.

The study is expected to result in the development of a panel of markers of healthy longevity and/or a model of healthy aging based on the analysis of all factors under consideration.

Full description

The study involves a long-term observation of a cohort of long-living adults. During the first visit, a medical professional will take a detailed medical history and perform a comprehensive geriatric assessment (for 15 geriatric syndromes), and physical examination. The participants will have their biomaterials sampled for basic and extended blood biochemistry testing, telomere length measurement, common urine tests and subsequent biobanking and additional studies: whole genome sequencing, DNA methylation analysis, transcriptome analysis, and 16S RNA sequencing of stool and saliva.

Follow-up checks will be carried out once a year by phone or during additional visits.

The study seeks to identify the genetic, epigenetic, and metagenomic determinants associated with the successful and unsuccessful aging phenotypes, mortality, and survival in long-living individuals.

Enrollment: 4,000 estimated patients

Sex: All

Ages: 90+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent
• 90 years of age or above

Exclusion criteria

• Refusal to participate or to provide informed consent;
• Any other criteria deemed reasons for exclusion by the Principal Investigator.

Trial design

4,000 participants in 1 patient group

Long-living individuals

Description:

Long-living individuals at least 90 years of age from the Central Federal District of Russia